Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
CompanyDeals

Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings
Company

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Legal / IP

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China

Bristol-Myers Squibb's Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
CompanyDrug

BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia
CompanyDrug

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
CompanyDeals

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies

BrightGene's BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
CompanyDrug

BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes

Dizal Pharmaceutical's Sunvozertinib Earns Breakthrough Designation for NSCLC from China's NMPA
CompanyDrug

Dizal Pharmaceutical’s Sunvozertinib Earns Breakthrough Designation for NSCLC from China’s NMPA

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures
Policy / Regulatory

NMPA Sets Forthcoming Guidelines for Domestic Drug Refiling Procedures

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation
CompanyDeals

Huawei Partners with Medical University Hospital to Boost Healthcare Innovation

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment
CompanyDrug

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment